References

  1. INFLECTRA [prescribing information]. Incheon, Republic of Korea: Celltrion, Inc.; 2019.
  2. The Weinberg Group. FDA approves INFLECTRA™, the second US biosimilar. . Published April 7, 2016. Accessed July 31, 2019.
  3. Celltrion. CT-P13 (infliximab biosimilar). Briefing document for the US FDA Arthritis Advisory Committee. . Published February 9, 2016. Accessed July 31, 2019.
  4. Ryan AM. Frontiers in nonclinical drug development: biosimilars. Vet Pathol. 2015;52(2):419-426.
  5. Food and Drug Administration (FDA). Biologics Website. . Accessed July 31, 2019.
  6. European Medicines Agency, European Commission. Biosimilars in the EU. Information guide for healthcare professionals. 2017. . April 27, 2017. Accessed July 31, 2019.
  7. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-419.
  8. Data on file. Pfizer Inc., New York, NY.
  9. US Food and Drug Administration. FDA briefing document. Arthritis Advisory Committee meeting. BLA 125544: CT-P13, a proposed biosimilar to Remicade® (infliximab), Celltrion. . Published February 9, 2016. Accessed July 31, 2019.
  10. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to Reference Product. Guidance for Industry. . Published April 2015. Accessed July 31, 2019.
  11. Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393:1699-1707.
  12. Data on file. Pfizer Inc., New York, NY.
  13. Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13* compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority. . 2017;389(10086):2304-2316.